[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypothermia-treatment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypothermia-treatment":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100567222","prognostic-biomarkers-for-selective-intra-arterial-cooling-infusion-combined-with-endovascular-thrombectomy-in-acute-ischemic-stroke-based-on-proteomics-and-metabolomics-100567222",false,"NCT06665386","Prognostic Biomarkers for Selective Intra-Arterial Cooling Infusion Combined with Endovascular Thrombectomy in Acute Ischemic Stroke Based on Proteomics and Metabolomics.","Inclusion Criteria:\n\n* Age ≥18 and ≤80.\n* Clinical signs consistent with acute ischemic stroke with large vessel occlusion in the anterior circulation (intracranial segment of the internal carotid artery, middle cerebral artery M1 segment) demonstrated with CTA\u002FMRA\u002FDSA.\n* NIHSS score obtained prior to randomization ≥6 and ≤25.\n* Modified Rankin Scale ≤ 1 prior to qualifying stroke.\n* Arterial puncture performed within 24 hours from symptom onset or LKW.\n* For the patients with symptom onset within 6 hours, the ASPECT score ≥6; for the patientswith onset within 6-24 hours, the therapy should meet the imaging criteria of DAWN or DEFUSE-3 trial.\n* Patient\u002FLegally Authorized Representative has signed the Informed Consent Form.\n\nExclusion Criteria:\n\n* Baseline CT\u002FMRI confirms the presence of multiple vascular territory acute strokes.\n* Baseline CT\u002FMRI confirms the presence of arterial dissection.\n* Evidence of intracranial hemorrhage or hemorrhagic transformation before thrombectomy.\n* Known allergies or intolerances to antiplatelet agents, anticoagulation drugs, iodinated contrast and\u002For anesthetics.\n* Severe infection (e.g. sepsis) or multiple organ failure.\n* Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; recent oral anticoagulant therapy with INR \\> 3. Patients on factor Xa inhibitor for 48 hours ago must have a normal APTT.\n* Baseline platelet count \\\u003C50 × 109\u002FL.\n* Blood glucose concentration\\\u003C50 mg\u002FdL (2.7mmol\u002FL) or \\>400 mg\u002FdL (22.2mmol\u002FL).\n* Refractory hypertension that is difficult to control by medication (Defined as persistent systolic blood pressure\\>185 mmHg or diastolic blood pressure\\>110mmHg).\n* Previous NHYA\\>1.\n* Untreated moderate or severe coronary artery stenosis, or previous coronary artery bypass surgery.\n* Undergoing hemodialysis or peritoneal dialysis; known severe renal insufficiency with glomerular filtration rate \\\u003C30 ml\u002Fmin or serum creatinine \\>220 mmol\u002FL (2.5mg\u002Fdl).\n* Known intracranial aneurysm, and cerebral arteriovenous malformation.\n* Malignant brain tumor or CNS infection.\n* Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations (e.g., dementia or mental illness)\n* Female who is pregnant or lactating at time of admission.\n* Anticipated life expectancy \\\u003C6 months.\n* Current participation in another investigational drug or device study.\n* For other reasons, the responsible clinicians believe that the patient is not suitable for continued treatment.","ALL","18 Years","80 Years",{"count":19,"type":20},258,"ESTIMATED","OBSERVATIONAL","Endovascular Thrombectomy has emerged as a pivotal treatment modality for acute ischemic stroke. However, despite successful thrombus removal, a substantial proportion of patients still experience poor outcomes. Selective intra-arterial cooling has shown promise in decelerating stroke progression and providing neuroprotection. This study aims to identify biomarkers associated with the combination of selective intra-arterial cooling infusion and endovascular thrombectomy in the treatment of ischemic stroke by integrating proteomics and metabolomics data. Our study is based on the multicenter RCT study \"Safety and Efficacy of Selective Intra-Arterial Cooling Infusion Combined With EVT in Acute Ischemic Stroke.\" All samples were derived from this experiment. Our objective is to elucidate the molecular mechanisms underlying the prognostic impact of this combined therapeutic approach, providing insights to optimize stroke treatment strategies.",[24,25],"Stroke","Hypothermia Treatment","RECRUITING","2024-12-09",{"date":29,"type":30},"2024-12-12","ACTUAL",{"date":32,"type":30},"2024-10-27",{"date":34,"type":20},"2025-02-28",{"name":36,"class":37},"Capital Medical University","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":47,"conditions":48,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":38},"100563060","quantification-of-brain-and-kidney-perfusion-before-during-and-after-hypothermia-treatment-in-neonates-with-perinatal-asphyxia-using-contrast-enhanced-ultrasound-100563060","NCT06611254","Quantification of Brain and Kidney Perfusion Before, During, and After Hypothermia Treatment in Neonates With Perinatal Asphyxia Using Contrast-enhanced Ultrasound","Inclusion Criteria:\n\n* Fulfillment of the inclusion criteria for hypothermia treatment according to the AWMF guideline\n* Severe acidosis (pH ≤7.0 or a base deficit ≥16 mmol\u002Fl) in umbilical cord blood or a blood sample from the first hour of life, and\n* clinical signs of moderate or severe encephalopathy (severity grade 2 or 3 according to Sarnat \\& Sarnat), and\n* postnatal age ≤6h, and\n* gestational age ≥36 weeks' gestation\n* Consent of the parents\u002Flegal guardians\n* Time 1 (before the start of hypothermia treatment)\n\n  * Informing the parents\u002Flegal guardians present on site despite an emotionally stressful situation with high individual benefit for the patient\n  * If only one parent is present and able to provide information, their consent is sufficient - the second parent is informed repeatedly when they regain the ability to provide information\n  * Information adapted to the emergency situation, addressing the personal situation and comprehensible presentation of the plan\n* Time 2 (during hypothermia treatment)\n\n  --\\>Offer of a further informative discussion\u002Frepeated explanation with the parents\u002Flegal representatives before the second measurement in order to answer any questions that may have arisen\n* Suitable acoustic window\n* Availability of the qualified examiner\n\nExclusion Criteria:\n\n* Lack of consent of at least one parent\n* Pre-existing brain malformations\n* Absence of the competent examiner",{"count":46,"type":20},20,"In this clinical study vascular dynamics in the neonatal brain and kidney will be monitored by CUES and ULM before, during and after hypothermia treatment in neonates with asphyxia.",[49,25,50],"Perinatal Asphyxia","Gestational Age Min. 36SSW","2024-09-20",{"date":53,"type":30},"2024-09-24",{"date":55,"type":30},"2024-06-24",{"date":57,"type":20},"2027-12-01",{"name":59,"class":37},"University of Erlangen-Nürnberg Medical School"]